SCHEMBL1900472

SCHEMBL1900472

NC(=O)c1nccc(N2C(=O)CCC2=O)c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.38
GRM4 Q14833 1/20 0.37
MAPK1 P28482 1/20 0.36
MAP2K1 Q02750 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
MAP2K3 P46734 1/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 1/20 0.35
IKBKB O14920 2/20 0.35
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAT2A P31153 1/20 0.33
MAP2 P11137 1/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908177 0.80 ADORA2A (0.35) ADORA2AGRM4MAP2K1CLK4DYRK1B
SCHEMBL1900466 0.78 ADORA2A (0.38) ADORA2AMAP2K1CLK4DYRK1BMAP2K3
SCHEMBL979253 0.75 MAPK9 (0.38) ADORA2AMAP2K1CLK4DYRK1BMAP2K3
SCHEMBL23067310 0.73 MAP2K3 (0.50) ADORA2AMAP2K1CLK4DYRK1BMAP2K3
SCHEMBL2848953 0.73 ADORA2A (0.46) ADORA2AMAP2K1CLK4DYRK1BMAP2K3
SCHEMBL1905180 0.72 NUDT1 (0.51)
SCHEMBL5791654 0.71 CA12 (0.41) GRM4MAPK1KMT2AMAPTRAB9A
SCHEMBL3971167 0.70 ADORA2A (0.41) ADORA2AMAP2K1CLK4DYRK1BMAP2K3
SCHEMBL1046126 0.70 CPB1 (0.38) ADORA2ANTRK1PIM1MAT2A
Formamide SCHEMBL29058737 0.69 ADORA2A (0.42) ADORA2AMAP2K1CLK4DYRK1BMAP2K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIA4, GRIK4 ADORA2A 187/4885GRM4 1/4885MAPK1 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.